恒瑞医药(600276.SH)：注射用瑞康曲妥珠单抗纳入突破性治疗品种名单

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received a breakthrough therapy designation from the National Medical Products Administration for its injectable drug SHR-A1811, marking the 10th indication for this drug to receive such certification [1] Group 1 - The drug SHR-A1811 is indicated for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring HER2 (ERBB2) activating mutations [1]